SAN DIEGO and PENNINGTON, N.J., Aug.
31, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, today announced that Daniel J. O'Connor, President and Chief
Executive Officer of OncoSec, will present a corporate overview at
the H.C. Wainwright 20th Annual Global Investment Conference on
Thursday, September 6, 2018 at
11:15 a.m. ET in New York City.
A live audio webcast of the presentation will be available on
the Investors section of OncoSec's website at ir.oncosec.com, where
it will be archived for approximately 30 days.
About OncoSec Immunotherapies
OncoSec is a
clinical-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy platform – TAVO (tavokinogene telseplasmid) – enables
the intratumoral delivery of DNA-based interleukin-12 (IL-12), a
naturally occurring protein with immune-stimulating functions. The
technology, which employs electroporation, is designed to produce a
controlled, localized expression of IL-12 in the tumor
microenvironment, enabling the immune system to target and attack
tumors throughout the body. OncoSec has built a deep and diverse
clinical pipeline utilizing TAVO as a potential treatment for
multiple cancer indications either as a monotherapy or in
combination with leading checkpoint inhibitors; with the latter
potentially enabling OncoSec to address a great unmet medical need
in oncology: anti-PD-1 non-responders. Results from recently
completed clinical studies of TAVO have demonstrated a local immune
response, and subsequently, a systemic effect as either a
monotherapy or combination treatment approach. In addition to
TAVO, OncoSec is identifying and developing new DNA-encoded
therapeutic candidates and tumor indications for use with its
ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-hc-wainwright-20th-annual-global-investment-conference-300705316.html
SOURCE OncoSec Medical Incorporated